Dr Reddy's Laboratories Makes Strategic $32.15 Million Move into Hormone Replacement Therapy Market
In a significant expansion of its pharmaceutical portfolio, Dr Reddy's Laboratories Ltd has announced its entry into India's hormone replacement therapy (HRT) segment through a strategic acquisition. The company has secured the trademarks and related assets for two prominent HRT brands, Progynova and Cyclo-Progynova, from the UK-based Mercury Pharma Group Limited for a substantial consideration of $32.15 million, approximately equivalent to Rs 295 crore.
Strengthening Gynaecology Portfolio with Strategic Acquisition
This calculated move is specifically designed to fortify Dr Reddy's gynaecology portfolio while simultaneously establishing a robust platform for expansion within the growing HRT segment. According to a regulatory filing submitted on Wednesday, the company aims to better serve patients experiencing symptoms associated with estrogen deficiency and menopause through this acquisition.
The therapeutic brands acquired represent two distinct approaches to hormone replacement therapy:
- Progynova (estradiol valerate) functions as an oral HRT medication primarily indicated for treating estrogen deficiency symptoms and preventing postmenopausal osteoporosis.
- Cyclo-Progynova (estradiol valerate and norgestrel) operates as a combined HRT treatment that incorporates both estrogen and progestogen components, specifically targeting estrogen deficiency symptoms.
Executive Leadership Views Acquisition as Strategic Spearhead
MV Ramana, Chief Executive Officer of Branded Markets (India and Emerging Markets) at Dr Reddy's, emphasized the strategic importance of this acquisition. He described the move as a "spearhead" for the company's expansion into the hormone replacement therapy domain, noting that Dr Reddy's intends to leverage its extensive market access capabilities to broaden reach and bring what he termed "first-in-class" treatment options closer to patients across India.
Market performance data reveals significant commercial potential for these brands. According to IQVIA MAT December 2025 statistics, the combined brands achieved sales of Rs 100 crore, demonstrating substantial market presence and consumer acceptance within the therapeutic category.
This acquisition represents a calculated diversification strategy for Dr Reddy's Laboratories as it seeks to capture a larger share of India's specialized pharmaceutical markets while addressing the healthcare needs of women experiencing menopausal symptoms and related conditions.
